What's new

Human medicines European public assessment report (EPAR): Hyrimoz, adalimumab, Date of authorisation: 26/07/2018, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Hyrimoz, adalimumab, Date of authorisation: 26/07/2018, Revision: 16, Status: Authorised

Apr 29, 2025 - 16:39
 0
Human medicines European public assessment report (EPAR): Hyrimoz, adalimumab, Date of authorisation: 26/07/2018, Revision: 16, Status: Authorised
Human medicines European public assessment report (EPAR): Hyrimoz, adalimumab, Date of authorisation: 26/07/2018, Revision: 16, Status: Authorised
Read More

Tags:

Previous Article

Pfizer, in sweeping cost cutting push, lifts overall savings target to $7.7B

Next Article

Human medicines European public assessment report (EPAR): Alofisel, darvadstroce...

Related Posts

Human medicines European public assessment report (EPAR): Denosumab BBL, denosumab, Status: Opinion

Human medicines European public assessment report (EPAR...

Apr 25, 2025  0

Human medicines European public assessment report (EPAR): Twynsta, telmisartan,amlodipine, Date of authorisation: 07/10/2010, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 28, 2025  0

Human medicines European public assessment report (EPAR): Zinplava, bezlotoxumab, Date of authorisation: 18/01/2017, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 23, 2025  0